|
|
|
| Gene analysis of Carbapenem resistance to Klebsiella pneumoniae in a general hospital |
| ZHANG Mei1, XIE Xianghong1, WEI Wenbo1, ZHANG Xin2, ZOU Yan1, HE Yanhong1, DENG Yong1 |
1. Department of Clinical Laboratory,Sichuan Provincial Corps Hospital,Chinese People’s Armed Police Force,Leshan 614000,China;
2. Department of Laboratory Medicine,Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital,Chengdu 610072,China |
|
|
|
|
Abstract Objective To detect the drug-resistant gene of Carbapenem-resistant Klebsiella pneumoniae (CRKP) in a hospital,to find out about the prevalence and distribution of the CRKP genes,and to provide data for treatment and prevention of related infections.Methods In this retrospective cohort study,32 strains of CRKP were collected from 13 departments of a general hospital between August 2017 and March 2020.The Microscan Walk Away96 automatic bacterial identification drug sensitivity analyzer was used for routine drug sensitivity tests.The modified carbapenem inactivation method (mCIM) combined with the enzyme inhibitor enhancement test was used to determine the production of the metal β-lactamase and serine cabapenemase.The Gene-Xpert Carba-XVIR2 automatic pathogen rapid detection system was used to detect drug-resistant genes.Results Drug sensitivity tests showed that the strains of CRKP collected from this hospital were highly resistant to carbapenems,cephalosporins,cephamycins,monocyclics,quinolones,and aminoglycosides antibiotics.Thirty of the 32 strains of CRKP were positive.One strain produced class A serine enzyme plus class B β-lactamase while 29 strains produced class A serine enzyme during the enzyme inhibitor enhancement test.One strain produced KPC+NDM,29 strains produced KPC,but no strains produced IMP,VIM or OX-48 from the Gene-Xpert system.Conclusions CRKP strains collected from this hospital are highly resistant to routinely used antibiotics.The main drug-resistant genotype is KPC type and the main mechanism of action is through carbapenemase production.In hospitals that are incapable of genotype analysis,mCIM can be combined with enzyme inhibitor enhancement tests to meet the clinical needs.
|
|
Received: 16 October 2020
|
|
|
|
|
|
| [1] |
胡付品,朱德妹.医疗机构碳青霉烯类耐药肠杆菌科细菌感染防控指南简介[J].中国感染与化疗杂志,2018,18(3):331-335.
|
| [2] |
姚 科,徐 琳.多种抗生素联合应用对耐碳青霉烯类肺炎克雷伯菌的体外抗菌活性研究[J].临床合理用药,2018,11(2):80-81.
|
| [3] |
毕颖敏,沈 震,董 栋,等.碳青霉烯类耐药肺炎克雷伯菌药物敏感性及blaKPC基因检出率[J].中国感染与化疗杂志,2017,17(3):298-302.
|
| [4] |
凌 勇,肖洪广,邱芳华,等.耐碳青霉烯肺炎克雷伯菌耐药基因分析[J].热带医学杂志,2018,18(3):358-361
|
| [5] |
康蓓佩,付晓蕊,贺文芳,等.耐碳青霉烯类的肺炎克雷伯菌的感染特点及耐药基因分析[J].国际检验医学杂志,2019,40(24):2991-2994
|
| [6] |
Poirel L,Lienhard R,Potron A,et al.Plasmid-mediated carbapenem-hydrolysing β-lactamase KPC-2 in a klebsiella pneumoniae isolate from Switzerland[J].J Antimicrob Chemother,2011,66(3):675-676.
|
| [7] |
Chen J F,Yang L H,ChangL X,et al.The clinical significance of circulating B cells secreting anti-glycoprotein Ⅱ b/Ⅲa antibody and platelet glycoprotein Ⅱ b/Ⅲa in patients with primary immune thrombocytopenia[J].Hematology,2012,17(5):283-290.
|
| [8] |
Adetifa I M,Ota M O,Jeffries D J,et al.Interferon-gamma ELISPOT as a biomarker of treatment efficacy in latent tuberculosis infection:a clinical trial[J].Am J Respir Crit Care Med,2013,187(4):439-445.
|
| [9] |
Ambler R P,Coulson A F,Frere J M,et al.A standard numbering scheme for the class A β-lactamases[J].Biochem J,1991,276(ptl):269-270.
|
| [10] |
王永红,刘 航,邹家齐,等,mCIM与eCIM检测肠杆菌科碳青霉烯酶的临床评价[J].第三军医大学学报,2020,42(5):466-472.
|
|
|
|
2021, Vol. 32 
